GDNF and Parkinson disease: These findings, together with the confirmation of the hypothesis underlying the previously observed cerebellar lesions, suggest that it is appropriate to use the (higher) NOAEL defined in the 6-month continuous IPu dosing toxicity study rather than the present (lower) NOAEL for the determination of safety margins for clinical use of GDNF in patients with PD.